‘Reduced malignancy as a mechanism for longevity in mice with adenylyl cyclase type 5 disruption’
Article first published online: 13 OCT 2013
© 2013 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Volume 13, Issue 1, pages 102–110, February 2014
How to Cite
De Lorenzo, M. S., Chen, W., Baljinnyam, E., Carlini, M. J., La Perle, K., Bishop, S. P., Wagner, T. E., Rabson, A. B., Vatner, D. E., Puricelli, L. I. and Vatner, S. F. (2014), ‘Reduced malignancy as a mechanism for longevity in mice with adenylyl cyclase type 5 disruption’. Aging Cell, 13: 102–110. doi: 10.1111/acel.12152
- Issue published online: 16 JAN 2014
- Article first published online: 13 OCT 2013
- Accepted manuscript online: 19 AUG 2013 10:23PM EST
- Manuscript Accepted: 10 AUG 2013
- National Institutes of Health. Grant Number: AG027211
- Diversity Supplement Program. Grant Number: AG027211-02S1
- The Josiah Macy, Jr. Foundation. Grant Number: 5-46787-B
- New Jersey Medical School Hispanic Center of Excellence
- Health Resources and Services Administration. Grant Number: D34HP16048
- AC5 inhibitor;
- adenylyl cyclase (AC) knockout mice;
- B16F10 melanoma;
- LP07 lung adenocarcinoma;
- MMTV-HER-2 neu mice;
- tumor protection
Disruption of adenylyl cyclase type 5 (AC5) knockout (KO) is a novel model for longevity. Because malignancy is a major cause of death and reduced lifespan in mice, the goal of this investigation was to examine the role of AC5KO in protecting against cancer. There have been numerous discoveries in genetically engineered mice over the past several decades, but few have been translated to the bedside. One major reason is that it is difficult to alter a gene in patients, but rather a pharmacological approach is more appropriate. The current investigation employs a parallel construction to examine the extent to which inhibiting AC5, either in a genetic knockout (KO) or by a specific pharmacological inhibitor protects against cancer. This study is unique, not only because a combined genetic and pharmacological approach is rare, but also there are no prior studies on the extent to which AC5 affects cancer. We found that AC5KO delayed age-related tumor incidence significantly, as well as protecting against mammary tumor development in AC5KO × MMTV-HER-2 neu mice, and B16F10 melanoma tumor growth, which can explain why AC5KO is a model of longevity. In addition, a Food and Drug Administration approved antiviral agent, adenine 9-β-D-arabinofuranoside (Vidarabine or AraAde), which specifically inhibits AC5, reduces LP07 lung and B16F10 melanoma tumor growth in syngeneic mice. Thus, inhibition of AC5 is a previously unreported mechanism for prevention of cancers associated with aging and that can be targeted by an available pharmacologic inhibitor, with potential consequent extension of lifespan.